{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137044530342784.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s12185-009-0359-5"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12185-009-0359-5.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s12185-009-0359-5/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12185-009-0359-5"}},{"identifier":{"@type":"PMID","@value":"20191334"}}],"dc:title":[{"@value":"Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma"}],"description":[{"notation":[{"@value":"Reactivation of hepatitis B virus (HBV) has been reported not only in HBsAg-positive patients undergoing systemic chemotherapy, but also in a proportion of HBsAg-negative patients with HBc antibody and/or HBs antibody. Recently, rituximab-plus-steroid combination chemotherapy (R-CHOP, etc.) has been identified as a risk factor for HBV reactivation in HBsAg-negative patients with malignant lymphoma. Prophylaxis with antiviral drugs is essential for preventing HBV reactivation in HBsAg-positive patients, but there is little evidence on which to base the choice of drug or appropriate duration of prophylaxis. There are also few clinical data on HBsAg-negative patients and no established standard of care for such patients with HBV reactivation. Based on the limited number of previous reports, preemptive therapy, guided by serial HBV-DNA monitoring, is a reasonable strategy to prevent HBV reactivation in HBsAg-negative patients. However, clinical evidence alone is insufficient for determining optimal frequency of HBV-DNA monitoring during and after chemotherapy, or for determining when to stop preemptive therapy for HBV reactivation. Thus, well-designed clinical trials should be carried out to investigate the efficacy and safety of such preemptive therapy. Additionally, assessment of viral factors such as HBV genotypes and gene mutations may assist in the development of strategies to prevent the occurrence of severe hepatitis. In this review, we summarize the characteristics of HBV reactivation after systemic chemotherapy including rituximab, and propose a management strategy for malignant lymphoma patients suffering from HBV reactivation."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137044530342914","@type":"Researcher","foaf:name":[{"@value":"Shigeru Kusumoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044530342913","@type":"Researcher","foaf:name":[{"@value":"Yasuhito Tanaka"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044530342915","@type":"Researcher","foaf:name":[{"@value":"Masashi Mizokami"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137044530342912","@type":"Researcher","foaf:name":[{"@value":"Ryuzo Ueda"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09255710"},{"@type":"EISSN","@value":"18653774"}],"prism:publicationName":[{"@value":"International Journal of Hematology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2009-06-23","prism:volume":"90","prism:number":"1","prism:startingPage":"13","prism:endingPage":"23"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s12185-009-0359-5.pdf"},{"@id":"http://link.springer.com/article/10.1007/s12185-009-0359-5/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s12185-009-0359-5"}],"createdAt":"2009-06-22","modifiedAt":"2019-06-02","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20virus","dc:title":"Hepatitis B virus"},{"@id":"https://cir.nii.ac.jp/all?q=Lymphoma","dc:title":"Lymphoma"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B","dc:title":"Hepatitis B"},{"@id":"https://cir.nii.ac.jp/all?q=Antiviral%20Agents","dc:title":"Antiviral Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20Antigens","dc:title":"Hepatitis B Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=DNA,%20Viral","dc:title":"DNA, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Virus%20Activation","dc:title":"Virus Activation"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002215326388096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002218323019648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232280833152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation from occult HBV carrier status is characterized by low genetic heterogeneity with the wild-type or G1896A variant prevalence"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235524781568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142633480320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283693322566144","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Novel monitoring of hepatitis B reactivation based on ultra‐high sensitive hepatitis B surface antigen assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285705164512640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706258427776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term follow-up of EBV-positive lymphoproliferative disorders in a patient with systemic lupus erythematosus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710588048384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Changing etiologies and outcomes of acute liver failure: A perspective from Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285710647041536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711733152384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617898603648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643857554816","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prolonged incubation period of hepatitis B in a recipient of a nucleic acid amplification test‐negative hepatitis B virus window donation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294740489334912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181473724928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182128604032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Considering economic analyses in the revision of the preventive vaccination law: A new direction for health policy-making in Japan?"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185478217984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Fatal reactivation of hepatitis B virus infection in a patient with adult T‐cell leukemia–lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185479120640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical evaluation of a novel and highly sensitive immunoassay for anti‐hepatitis B core antigen using a fully automated immunochemical analyzer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567186831729408","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical Significance of Hepatitis B Virus (HBV) -DNA Monitoring to Detect HBV Reactivation After Systemic Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568466082640384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360568470398830848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevalence of infectious diseases in patients with autoimmune blistering diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256755584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846642463453952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848655117244800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660454235392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reactivation of hepatitis <scp>B</scp> virus in a patient with adult <scp>T</scp>‐cell leukemia–lymphoma receiving the anti‐<scp>CC</scp> chemokine receptor 4 antibody mogamulizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848664146523648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567371764608","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861705581553152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792912128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Universal hepatitis B vaccination: pros and cons"},{"@language":"ja","@value":"ユニバーサルＨＢワクチネーション：是か非か？"},{"@language":"ja-Kana","@value":"ユニバーサル HB ワクチネーション ゼ カ ヒ カ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204876526208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Late Reactivation of Hepatitis B Virus after Chemotherapies for Hematological Malignancies: A Case Report and Review of the Literature"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205078172416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Present state and the future direction of HBV vaccine"},{"@language":"ja","@value":"HBVワクチンの現状と今後の問題点"},{"@language":"ja-Kana","@value":"HBV ワクチン ノ ゲンジョウ ト コンゴ ノ モンダイテン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390003825180015232","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型肝炎再活性化発症に関連するウイルス側因子"},{"@language":"ja-Kana","@value":"Bガタ カンエン サイカッセイカ ハッショウ ニ カンレン スル ウイルスガワ インシ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390003825190125568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B virus reactivation in a myeloma patient with resolved                    infection who received daratumumab-containing salvage                    chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390020397612449792","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Seven cases illustrating difficulties in the treatment of MPO-ANCA-positive refractory otitis media"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679220206976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pretreatment Screening for Hepatitis B Virus Infection in Patients with Systemic Lupus Erythematosus"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679628657536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"IgG4関連疾患に対する新たな治療戦略"},{"@language":"en","@value":"New strategies for the treatment of IgG4-related disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770766080","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with membranous nephropathy treated with immunosuppression"},{"@value":"膜性腎症の治療経過中に発症したde novo B型肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク マクセイジンショウ ノ チリョウ ケイカ チュウ ニ ハッショウ シタ de novo Bガタ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679770778880","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Automated risk management of HBV reactivation by encoding patients' medical records"},{"@language":"ja","@value":"診療情報コード化による自動的HBV再活性化リスクマネージメント"},{"@language":"ja-Kana","@value":"シンリョウ ジョウホウ コードカ ニ ヨル ジドウテキ HBV サイカッセイカ リスクマネージメント"},{"@value":"Automated risk management of HBV reactivation by encoding patients^|^apos; medical records"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681423844480","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"1．免疫抑制剤使用時の肝炎ウイルス再活性化"},{"@language":"en","@value":"1. Reactivation of Hepatitis B Virus and Hepatitis C Virus Following Immunosuppressive Therapy"},{"@value":"免疫抑制剤使用時の肝炎ウイルス再活性化"},{"@language":"ja-Kana","@value":"メンエキ ヨクセイザイ シヨウジ ノ カンエンウイルス サイカッセイカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390300091972855808","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation"}]},{"@id":"https://cir.nii.ac.jp/crid/1390565134815340032","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"免疫抑制療法における B 型肝炎ウイルス再活性化の現状と方策"}]},{"@id":"https://cir.nii.ac.jp/crid/1390566775140586496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Fulminant Hepatitis due to <i>de novo</i> Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1390568456357560192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390845713049085952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390868826189491200","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Delayed Hepatitis B Virus Reactivation at 33 Months after the Completion of Rituximab-based Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390869378867452288","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"核酸アナログが処方されていたにもかかわらず早期に致死的HBV再活性化を来たしたB型慢性肝炎非活動性キャリアの一例"},{"@language":"en","@value":"A Case of Fatal Hepatitis B Virus Reactivation During Prophylactic Entecavir Prescription"},{"@language":"ja-Kana","@value":"カクサン アナログ ガ ショホウ サレテ イタ ニ モ カカワラズ ソウキ ニ チシテキ HBV サイカッセイカ オ キタ シタ Bガタ マンセイ カンエン ヒカツドウセイ キャリア ノ イチレイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1391975276375902208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficient Prophylactic Management of HBV Reactivation by an Information Technology Encoding System: Results of a 6-year Prospective Cohort Study"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367073795072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s12185-009-0359-5"},{"@type":"OPENAIRE","@value":"doi_dedup___::bc64598b8c538bcb2bcf528def778dc0"},{"@type":"CROSSREF","@value":"10.1007/s00535-010-0367-5_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1007/s10157-011-0464-7_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2012.00998.x_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/hepr.12496_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.4190-19_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2957/kanzo.61.237_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.3950/jibiinkoka.122.1548_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/cas.14846_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/liv.13349_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1002/jmv.25011_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1007/s00795-011-0551-6_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/j.1440-1746.2010.06574.x_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/j.1478-3231.2010.02417.x_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1182/asheducation-2014.1.576_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.4445-20_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.3960/jslrt.19034_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.74_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2177/jsci.39.485_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1007/s10147-020-01655-4_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1587-18_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/trf.16557_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/hepr.13761_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1248/bpb.b23-00907_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5179-24_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1007/s12185-015-1750-z_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/hepr.12513_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/hepr.13229_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1620/tjem.237.9_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1007/s12072-019-09988-7_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/1346-8138.15244_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2014.04.033_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.5387/fms.2023-21_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1007/s00535-016-1168-2_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1093/cid/civ344_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1002/jmv.21995_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/hepr.12117_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.5678-20_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.3109/14397595.2013.852834_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2957/kanzo.50.598_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2222/jsv.62.67_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2169/naika.103.1645_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/hepr.13575_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1111/jvh.13740_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2957/kanzo.66.501_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1016/j.healthpol.2014.07.016_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.1200/jco.2010.33.0332_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2957/kanzo.55.91_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.56.7468_references_DOI_4QlT4RTUpPLC3RK5TPp5shCfFi2"}]}